Tags

Type your tag names separated by a space and hit enter

Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.
Eur Urol. 2007 Jun; 51(6):1717-23.EU

Abstract

OBJECTIVES

This pilot study was undertaken to assess the efficacy and safety of the alpha(1)-blocker alfuzosin 10mg once daily (OD), the PDE-5 inhibitor sildenafil 25mg OD, and the combination of both on lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) and erectile dysfunction (ED).

MATERIAL AND METHODS

Men aged 50-76 yr with previously untreated LUTS and ED were randomized to receive alfuzosin (n=20), sildenafil (n=21), or the combination of both (n=21) for 12 wk. Changes from baseline in International Prostate Symptom Score (IPSS), voiding diary, maximum urinary flow rate (Qmax), postvoid residual urine (PVRU) volume, and erectile function domain of the International Index of Erectile Function (IIEF) were assessed at week 12.

RESULTS

Improvement of IPSS was significant with the three treatments but greatest with the combination (-24.1%) compared with alfuzosin (-15.6%) and sildenafil (-11.8%) [corrected] alone (p<0.03). Frequency, nocturia, PVR, and Qmax were significantly improved with alfuzosin only and the combination. Improvement in IIEF was slight with alfuzosin (16.7%), marked with sildenafil (49.7%), and greatest with the combination (58.6%). Likewise, increases in the frequency of penetration (Q3) and of maintained erection (Q4) were greater with the combination therapy (65.2% and 68.2%, respectively) than with sildenafil (41.7% and 59.1%, respectively) and alfuzosin (27.3% and 33.3%, respectively) alone. All three treatments were well tolerated.

CONCLUSIONS

In this pilot study, the combination of alfuzosin 10 mg OD and sildenafil 25 mg OD is safe and more effective than monotherapy with either agent to improve both voiding and sexual dysfunction in men with LUTS suggestive of BPH.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Kaplan SA
Department of Urology, Weill Cornell Medical College, New York, NY, USA. kaplans@med.cornell.edu
Gonzalez RR
No affiliation info available
Te AE
No affiliation info available

MeSH

Adrenergic alpha-AntagonistsAgedDrug Therapy, CombinationErectile DysfunctionHumansMaleMiddle AgedPhosphodiesterase InhibitorsPilot ProjectsPiperazinesProstatic HyperplasiaPurinesQuinazolinesSildenafil CitrateSulfonesTreatment OutcomeUrination Disorders

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

17258855

Citation

Kaplan, Steven A., et al. "Combination of Alfuzosin and Sildenafil Is Superior to Monotherapy in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction." European Urology, vol. 51, no. 6, 2007, pp. 1717-23.
Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol. 2007;51(6):1717-23.
Kaplan, S. A., Gonzalez, R. R., & Te, A. E. (2007). Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. European Urology, 51(6), 1717-23.
Kaplan SA, Gonzalez RR, Te AE. Combination of Alfuzosin and Sildenafil Is Superior to Monotherapy in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction. Eur Urol. 2007;51(6):1717-23. PubMed PMID: 17258855.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. AU - Kaplan,Steven A, AU - Gonzalez,Ricardo R, AU - Te,Alexis E, Y1 - 2007/01/16/ PY - 2006/10/15/received PY - 2007/01/05/accepted PY - 2007/1/30/pubmed PY - 2007/8/1/medline PY - 2007/1/30/entrez SP - 1717 EP - 23 JF - European urology JO - Eur Urol VL - 51 IS - 6 N2 - OBJECTIVES: This pilot study was undertaken to assess the efficacy and safety of the alpha(1)-blocker alfuzosin 10mg once daily (OD), the PDE-5 inhibitor sildenafil 25mg OD, and the combination of both on lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) and erectile dysfunction (ED). MATERIAL AND METHODS: Men aged 50-76 yr with previously untreated LUTS and ED were randomized to receive alfuzosin (n=20), sildenafil (n=21), or the combination of both (n=21) for 12 wk. Changes from baseline in International Prostate Symptom Score (IPSS), voiding diary, maximum urinary flow rate (Qmax), postvoid residual urine (PVRU) volume, and erectile function domain of the International Index of Erectile Function (IIEF) were assessed at week 12. RESULTS: Improvement of IPSS was significant with the three treatments but greatest with the combination (-24.1%) compared with alfuzosin (-15.6%) and sildenafil (-11.8%) [corrected] alone (p<0.03). Frequency, nocturia, PVR, and Qmax were significantly improved with alfuzosin only and the combination. Improvement in IIEF was slight with alfuzosin (16.7%), marked with sildenafil (49.7%), and greatest with the combination (58.6%). Likewise, increases in the frequency of penetration (Q3) and of maintained erection (Q4) were greater with the combination therapy (65.2% and 68.2%, respectively) than with sildenafil (41.7% and 59.1%, respectively) and alfuzosin (27.3% and 33.3%, respectively) alone. All three treatments were well tolerated. CONCLUSIONS: In this pilot study, the combination of alfuzosin 10 mg OD and sildenafil 25 mg OD is safe and more effective than monotherapy with either agent to improve both voiding and sexual dysfunction in men with LUTS suggestive of BPH. SN - 0302-2838 UR - https://www.unboundmedicine.com/medline/citation/17258855/Combination_of_alfuzosin_and_sildenafil_is_superior_to_monotherapy_in_treating_lower_urinary_tract_symptoms_and_erectile_dysfunction_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0302-2838(07)00036-X DB - PRIME DP - Unbound Medicine ER -